The dopamine transporter is differentially regulated after dopaminergic lesion

Neurobiology of Disease

Volumn 40, Issue 3, 2010, Pages 518-530

  Afonso Oramas, Domingo ^a   Cruz Muros, Ignacio ^a,c   Barroso Chinea, Pedro ^b,c   de la Rosa, Diego Álvarez ^a   Castro Hernández, Javier ^a   Salas Hernández, Josmar ^a   Giráldez, Teresa ^d   González Hernández, Tomás ^a,c  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

Author keywords

6 OHDA; Degeneration; Dopamine transporter; HEK cell; Mesostriatal; MPP+; Parkinson's disease; Rat; Vulnerability

Indexed keywords

DOPAMINE TRANSPORTER; NEUROTOXIN; OXIDOPAMINE; ROTENONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DEGENERATION; CELL MEMBRANE; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOWN REGULATION; ENDOPLASMIC RETICULUM; GOLGI COMPLEX; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MESENCEPHALON; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN TRANSPORT; RAT; SUBSTANTIA NIGRA; THALAMUS VENTRAL NUCLEUS;

ADRENERGIC AGENTS; ANIMALS; BLOTTING, WESTERN; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOWN-REGULATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INJECTIONS, INTRAVENTRICULAR; OXIDOPAMINE; PROTEIN TRANSPORT; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION;

EID: 77957819559     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.07.012     Document Type: Article

References (65)

1. Adams J.D., Chang M.L., Klaidman L. Parkinson's disease-redox mechanisms. Curr. Med. Chem. 2001, 8:809-814.
2. Amara S.G., Kuhar M.J. Neurotransmitter transporters: recent progress. Ann Rev Neurosci 1993, 16:73-93.
3. Berman S.B., Zigmond M.J., Hastings T.G. Modification of dopamine transporter function: effect of reactive oxygen species and dopamine. J. Neurochem. 1996, 67:593-600.
4. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 1973, 20:415-455.
5. Betarbet R., Sherer T.B., Greenamyre J.T. Animal models of Parkinson's disease. Bioessays 2002, 24:308-318.
6. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., Crossman A.R., Bioulac B., Brotchie J.M., Gross C.E. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Neurosci. 2001, 21:6853-6861.
7. Bezard E., Gross C.E., Brotchie J.M. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci. 2003, 26:215-221.
8. Bezard E., Gross C.E., Fournier M.C., Dovero S., Bloch B., Jaber M. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp. Neurol. 1999, 155:268-273.
9. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., Verna J.M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 2001, 65:135-172.
10. Cerruti C., Walther D.M., Kuhar M.J., Uhl G.R. Dopamine transporter mRNA expression is intense in rat midbrain neurons and modest outside midbrain. Brain Res. Mol. Brain Res. 1993, 18:181-186.
11. Cruz-Muros I., Afonso-Oramas D., Abreu P., Perez-Delgado M.M., Rodriguez M., Gonzalez-Hernandez T. Aging effects on the dopamine transporter expression and compensatory mechanisms. Neurobiol. Aging 2009, 30:973-986.
12. Chagkutip J., Vaughan R.A., Govitrapong P., Ebadi M. 1-Methyl-4-phenylpyridinium-induced down-regulation of dopamine transporter function correlates with a reduction in dopamine transporter cell surface expression. Biochem Bioph Res Co 2003, 311:49-54.
13. Chen M.K., Kuwabara H., Zhou Y., Adams R.J., Brasic J.R., McGlothan J.L., Verina T., Burton N.C., Alexander M., Kumar A., Wong D.F., Guilarte T.R. VMAT2 and dopamine neurons loss in a primate model of Parkinson's disease. J. Neurochem. 2008, 105:78-90.
14. Damier P., Hirsch E.C., Agid Y., Graybiel A.M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999, 122(Pt 8):1437-1448.
15. Daniels G.M., Amara S.G. Regulated trafficking of the human dopamine transporter. Clathrin-mediated internalization and lysosomal degradation in response to phorbol esters. J. Biol. Chem. 1999, 274:35794-35801.
16. Fallon J.H., Moore R.Y. Catecholamine innervation of the basal forebrain. IV. Topography of the dopamine projection to the basal forebrain and neostriatum. J. Comp. Neurol. 1978, 180:545-580.
17. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114(Pt 5):2283-2301.
18. Fleckenstein A.E., Kopajtic T.A., Boja J.W., Carroll F.I., Kuhar M.J. Highly potent cocaine analogs cause long-lasting increases in locomotor activity. Eur. J. Pharmacol. 1996, 311:109-114.
19. Fleckenstein A.E., Metzger R.R., Beyeler M.L., Gibb J.W., Hanson G.R. Oxygen radicals diminish dopamine transporter function in rat striatum. Eur. J. Pharmacol. 1997, 334:111-114.
20. Fleckenstein A.E., Metzger R.R., Wilkins D.G., Gibb J.W., Hanson G.R. Rapid and reversible effects of methamphetamine on dopamine transporters. J. Pharmacol. Exp. Ther. 1997, 282:834-838.
21. Gainetdinov R.R., Fumagalli F., Jones S.R., Caron M.G. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J. Neurochem. 1997, 69:1322-1325.
22. Gainetdinov R.R., Fumagalli F., Wang Y.M., Jones S.R., Levey A.I., Miller G.W., Caron M.G. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. J. Neurochem. 1998, 70:1973-1978.
23. Gainetdinov R.R., Jones S.R., Fumagalli F., Wightman R.W., Caron M.G. Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis. Brain Res Bras Res Rev 1998, 26:148-153.
24. Gerfen C.R. The neostriatal mosaic. I. Compartmental organization of projections from the striatum to the substantia nigra in the rat. J. Comp. Neurol. 1985, 236:454-476.
25. Gerfen C.R., Herkenham M., Thibault J. The neostriatal mosaic: II. Patch- and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems. J. Neurosci. 1987, 7:3915-3934.
26. Giros B., Caron M.G. Molecular characterization of the dopamine transporter. Trends Pharmacol. Sci. 1993, 14:43-49.
27. Gonzalez-Hernandez T., Barroso-Chinea P., De La Cruz Muros I., Del Mar Perez-Delgado M., Rodriguez M. Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons. J. Comp. Neurol. 2004, 479:198-215.
28. Granado N., Escobedo I., O'Shea E., Colado I., Moratalla R. Early loss of dopaminergic terminals in striosomes after MDMA administration to mice. Synapse 2008, 62:80-84.
29. Graybiel A.M., Moratalla R., Robertson H.A. Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. P Natl Acad Sci USA 1990, 87:6912-6916.
30. Gulley J.M., Doolen S., Zahniser N.R. Brief, repeated exposure to substrates down-regulates dopamine transporter function in Xenopus oocytes in vitro and rat dorsal striatum in vivo. J. Neurochem. 2002, 83:400-411.
31. Hirsch E., Graybiel A.M., Agid Y.A. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988, 334:345-348.
32. Hurd Y.L., Pristupa Z.B., Herman M.M., Niznik H.B., Kleinman J.E. The dopamine transporter and dopamine D2 receptor messenger RNAs are differentially expressed in limbic- and motor-related subpopulations of human mesencephalic neurons. Neuroscience 1994, 63:357-362.
33. Iravani M.M., Syed E., Jackson M.J., Johnston L.C., Smith L.A., Jenner P. A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets. Eur. J. Neurosci. 2005, 21:841-854.
34. Joel D., Weiner I. The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental organization of the striatum. Neuroscience 2000, 96:451-474.
35. Kimmel H., Vicentic A., Kuhar M.J. Neurotransmitter transporters synthesis and degradation rates. Life Sci. 2001, 68:2181-2185.
36. Kimmel H.L., Carroll F.I., Kuhar M.J. Dopamine transporter synthesis and degradation rate in rat striatum and nucleus accumbens using RTI-76. Neuropharmacology 2000, 39:578-585.
37. Kopin I.J. Features of the dopaminergic neurotoxin MPTP. Ann. NY Acad. Sci. 1992, 648:96-104.
38. Langer L.F., Graybiel A.M. Distinct nigrostriatal projection systems innervate striosomes and matrix in the primate striatum. Brain Res. 1989, 498:344-350.
39. Li L.B., Chen N., Ramamoorthy S., Chi L., Cui X.N., Wang L.C., Reith M.E. The role of N-glycosylation in function and surface trafficking of the human dopamine transporter. J. Biol. Chem. 2004, 279:21012-21020.
40. Luo Y., Roth G.S. The roles of dopamine oxidative stress and dopamine receptor signaling in aging and age-related neurodegeneration. Antioxid Redox Sign 2000, 2:449-460.
41. Marey-Semper I., Gelman M., Levi-Strauss M. A selective toxicity toward cultured mesencephalic dopaminergic neurons is induced by the synergistic effects of energetic metabolism impairment and NMDA receptor activation. J. Neurosci. 1995, 15:5912-5918.
42. Martres M.P., Demeneix B., Hanoun N., Hamon M., Giros B. Up- and down-expression of the dopamine transporter by plasmid DNA transfer in the rat brain. Eur. J. Neurosci. 1998, 10:3607-3616.
43. Melikian H.E., Buckley K.M. Membrane trafficking regulates the activity of the human dopamine transporter. J. Neurosci. 1999, 19:7699-7710.
44. Nakatsukasa K., Huyer G., Michaelis S., Brodsky J.L. Dissecting the ER-associated degradation of a misfolded polytopic membrane protein. Cell 2008, 132:101-112.
45. Przedborski S., Jackson-Lewis V. Mechanisms of MPTP toxicity. Mov. Disord. 1998, 13(Suppl 1):35-38.
46. Robinson T.E., Mocsary Z., Camp D.M., Whishaw I.Q. Time course of recovery of extracellular dopamine following partial damage to the nigrostriatal dopamine system. J. Neurosci. 1994, 14:2687-2696.
47. Rodriguez M., Abdala P., Barroso-Chinea P., Obeso J., Gonzalez-Hernandez T. Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: an animal model of Parkinson's disease. Behav. Brain Res. 2001, 122:79-92.
48. Rodriguez M., Barroso-Chinea P., Abdala P., Obeso J., Gonzalez-Hernandez T. Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in Parkinson's disease. Exp. Neurol. 2001, 169:163-181.
49. Sandoval V., Riddle E.L., Ugarte Y.V., Hanson G.R., Fleckenstein A.E. Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. J. Neurosci. 2001, 21:1413-1419.
50. Schmued L.C., Albertson C., Slikker W. Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res. 1997, 751:37-46.
51. Schmued L.C., Hopkins K.J. Fluoro-Jade: novel fluorochromes for detecting toxicant-induced neuronal degeneration. Toxicol. Pathol. 2000, 28:91-99.
52. Schober A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res. 2004, 318:215-224.
53. Stachowiak M.K., Keller R.W., Stricker E.M., Zigmond M.J. Increased dopamine efflux from striatal slices during development and after nigrostriatal bundle damage. J. Neurosci. 1987, 7:1648-1654.
54. Storch A., Kaftan A., Burkhardt K., Schwarz J. 6-Hydroxydopamine toxicity towards human SH-SY5Y dopaminergic neuroblastoma cells: independent of mitochondrial energy metabolism. J. Neural Transm. 2000, 107:281-293.
55. Storch A., Ludolph A.C., Schwarz J. HEK-293 cells expressing the human dopamine transporter are susceptible to low concentrations of 1-methyl-4-phenylpyridine (MPP+) via impairment of energy metabolism. Neurochem. Int. 1999, 35:393-403.
56. Uhl G.R. Dopamine transporter: basic science and human variation of a key molecule for dopaminergic function, locomotion, and parkinsonism. Mov. Disord. 2003, 18(Suppl 7):S71-S80.
57. Uhl G.R., Walther D., Mash D., Faucheux B., Javoy-Agid F. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons. Ann. Neurol. 1994, 35:494-498.
58. Ungerstedt U. Striatal dopamine release after amphetamine or nerve degeneration revealed a rotational behavior. Acta Physiol Scan. Suppl 1971, 367:49-68.
59. Wang Y.M., Gainetdinov R.R., Fumagalli F., Xu F., Jones S.R., Bock C.B., Miller G.W., Wightman R.M., Caron M.G. Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 1997, 19:1285-1296.
60. West M.J. Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias. Trends Neurosci. 1999, 22:51-61.
61. Williams R.W., Rakic P. Three-dimensional counting: an accurate and direct method to estimate numbers of cells in sectioned material. J. Comp. Neurol. 1988, 278:344-352.
62. Woodgate A., MacGibbon G., Walton M., Dragunow M. The toxicity of 6-hydroxydopamine on PC12 and P19 cells. Brain Res. Mol. Brain Res. 1999, 69:84-92.
63. Zhu S.J., Kavanaugh M.P., Sonders M.S., Amara S.G., Zahniser N.R. Activation of protein kinase C inhibits uptake, currents and binding associated with the human dopamine transporter expressed in Xenopus oocytes. J. Pharmacol. Exp. Ther. 1997, 282:1358-1365.
64. Zigmond M.J., Abercrombie E.D., Berger T.W., Grace A.A., Stricker E.M. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 1990, 13:290-296.
65. Zigmond M.J., Stricker E.M. Recovery of feeding and drinking by rats after intraventricular 6-hydroxydopamine or lateral hypothalamic lesions. Science 1973, 182:717-720.